idea-006 · viability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: the investor, and the operator who would have to sell a cheaper second device into a channel the first mover already holds.
How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-006.md — the number is the claim's position in its ## Claims list, the tag is copied from it and never adjusted here. A [no claim] marker means nothing in the file speaks to the condition at all. No number appears here that is not in a claim, and there is no ask slide. See docs/deck-spec.md.
What changed since the 2026-08-24 build: the incumbent is reported to hold a VA Federal Supply Schedule contract effective 2024-06-17, extended beyond VA to DoD, Bureau of Prisons, Indian Health Services and Public Health Service beneficiaries claim 40unconfirmed, and the class's clinical evidence is now specified claim 31unconfirmed, claim 33unconfirmed. Both strengthen the category and weaken the follower thesis. Rebuilt from the file, not patched.
Would have to be true: Two buyers, both institutional or self-pay: the VA, purchasing through prosthetics, and the private patient paying out of pocket through an audiology practice.
Where it stands: The VA schedule that covers this category is described claim 30unconfirmed — Schedule 65 II A, indefinite-delivery/indefinite-quantity contracts awarded to pre-approved vendors through full and open competition — and the incumbent is reported to be on it claim 40unconfirmed. Both claims are unconfirmed, and for different reasons worth distinguishing: no connector in this repo reads VA contracting at all, and the FSS award is sourced to a company press release rather than a government record. The private half rests on the candidate's own flagged assumption claim 17unconfirmed.
What would settle it: The VA National Acquisition Center's own FSS listing, read directly rather than through a press release; VA prosthetics purchasing rules; private-practice interviews for the second half.
If it's false: Both buyers are discretionary. There is no coverage floor under this product anywhere, which cuts both ways: no payer gate to clear, and no payer to fund it.
Would have to be true: Nothing, for the product itself — and that absence is the structural fact to price.
Where it stands: The Generator identified no CPT (Current Procedural Terminology) or HCPCS (Healthcare Common Procedure Coding System) code specific to a tinnitus treatment device and the claim is unchecked claim 7unconfirmed. Nothing since has changed that, and nothing will: the buying decision here is VA contracting, which no connector in this repo touches. The 2014 AAO-HNSF guideline offers no recommendation addressing bimodal neuromodulation at all claim 39unconfirmed, which is the kind of absence a payer cites when declining to create a benefit.
What would settle it: VA contracting, not CMS (Centers for Medicare & Medicaid Services). Nothing in this repo's connector set touches it.
If it's false: It is not false; it is the shape. The risk is treating "no reimbursement barrier" as good news when it also means no reimbursement.
Would have to be true: A large severity-qualified population, a defensible price, and a reachable initial share.
Where it stands: The population now has a sourced base and a sharp qualifier: 9.6% 12-month tinnitus prevalence among US adults from the 2007 NHIS (75,764 respondents), an estimated 21.4 of 222.1 million adults — of whom 7.2% rated their tinnitus a big or very big problem claim 38unconfirmed. The severity filter is what the intended use turns on, and it takes the denominator down by more than an order of magnitude before any share assumption is applied claim 10unconfirmed. Price claim 11unconfirmed and obtainable share claim 12unconfirmed remain Generator assumptions, and the VA half of the share argument now has to contend with an occupied contract claim 40unconfirmed. The VA population itself is still unread claim 8unconfirmed.
What would settle it: The VA Annual Benefits Report for the veteran population; VA prosthetics dispensing volumes for the treatment-seeking fraction; the incumbent's published price.
If it's false: TAM (total addressable market) is a hard kill condition, and here it rests on a number that is one free download from being real.
Would have to be true: The 510(k) (premarket notification) route into the new classification would have to hold — because the alternative changes the business by an order of magnitude.
Where it stands: The two-branch estimate is unbenchmarked claim 15unconfirmed, and the branch point is the electrode-site question claim 14unconfirmed. What is verified bounds only the container: the De Novo (De Novo classification request) grant and its date claim 1verified and the classification it created claim 2verified. Whether the predicate mechanism works for a follower claim 3unconfirmed and whether anyone has used it claim 4unconfirmed are both unread — and three years of silence in a classification created in March 2023 is the empirical half of that answer.
What would settle it: An FDA (US Food and Drug Administration) pre-submission on the electrode-site change — the single decision that sets which of the two numbers applies; a reading of part 860 by counsel for the predicate mechanism; and, cheapest first, the posted results of the completed non-intraoral bimodal trial claim 29unconfirmed, which bears on whether the cheap branch is even plausible.
If it's false: The investment case is not "cheap follower" but "second pivotal trial in a category with a first mover", which is a different business at a different price.
Would have to be true: Something would have to protect a company whose entire strategy is being a fast-follower itself.
Where it stands: The only moat claim in the file is this deck's own write-back, and it concedes the point: price and remote fitting rather than technology, since the classification is open to any entrant meeting the special controls claim 23unconfirmed. Both halves weakened since the last build. Price competition now runs against an incumbent with a federal contract covering five beneficiary populations claim 40unconfirmed; remote fitting runs against the adjacent regulation's professional-fitting special control claim 5verified. FTO (freedom to operate) — the one structural protection available — was never asked claim 28unconfirmed.
What would settle it: A patent landscape on bimodal acoustic-electrical timing, where the incumbent's position is the obvious blocking surface; the QVN special controls, which set the bar every subsequent entrant must clear.
If it's false: A price-competitive follower with no structural protection, in a category where the incumbent holds the trial claim 31unconfirmed, the real-world series claim 33unconfirmed and the channel claim 40unconfirmed.
Would have to be true: The incumbent's position would have to be beatable on price and channel, given it holds first-mover status, a published pivotal trial and an established VA relationship.
Where it stands: Every element of that sentence is now documented rather than assumed, and the position is stronger than the last build could show. The pivotal trial: 326 adults, randomized, double-blinded, Cohen's d -0.87 to -0.92 on the THI at 12 weeks, P<.001 claim 31unconfirmed. Real-world performance: a 220-patient US retrospective series with a 91.5% responder rate (95% CI 86.9%-94.5%) claim 33unconfirmed. Compliance: 83.8% in a randomized settings trial claim 32unconfirmed. And the channel: a VA FSS contract effective 2024-06-17, extended to DoD, Bureau of Prisons, Indian Health Services and Public Health Service beneficiaries claim 40unconfirmed. Against that, the comparators the guideline actually recommends underperform — CBT at 5.65 THI points, below its own 7-point MCID claim 35unconfirmed, and sound therapy with no evidence of superiority to waiting-list or placebo claim 36unconfirmed — which makes the category attractive and the incumbent's position within it the thing to beat claim 16unconfirmed.
What would settle it: The QVN special controls and the De Novo decision summary, read directly, for what a follower must show; the FSS listing read from the VA rather than from a press release claim 9unconfirmed.
If it's false: Read it inverted — the risk is not a crowded field but an empty one that stayed empty for three years claim 4unconfirmed, in a classification that has existed since 2023 claim 1verified, while the incumbent consolidated evidence and channel.
Would have to be true: Three free documents would have to decide the investment case.
Where it stands: The list is longer than it was and all of it is still free. Unread: the De Novo decision summary and QVN special controls; the VA FSS listing at the National Acquisition Center; the VA Annual Benefits Report claim 8unconfirmed; and — new, and the highest ratio of the four — the posted results of NCT03621735 (a ClinicalTrials.gov registration number), a completed 100-participant randomized crossover trial of non-intraoral bimodal stimulation claim 29unconfirmed, which bears directly on the branch point that sets the capital number.
What would settle it: Read all four, then take the electrode-site question to an FDA pre-submission claim 15unconfirmed.
If it's false: Nothing here is false — this is a work order, and it is almost entirely reading.
Every condition above with nothing verified behind it.
adoption-refused, primary research only.
Thirteen new claims since the last build and not one moved a tag — they are literature, registry records and company press, none of which any connector here can verify. What they did instead is make the incumbent's position legible. The category's evidence is good and all of it belongs to somebody else.
If only one thing from this chair could be checked: whether a De Novo grantee's device is actually available as a predicate for a follower 510(k) into QVN claim 3unconfirmed, claim 4unconfirmed.
It survives as load-bearing: the candidate is a follower strategy, and if there is no follower path there is no candidate. The legal mechanism is unsettled on this file's own reading of 21 CFR (Title 21 of the Code of Federal Regulations) part 860 claim 3unconfirmed, and the empirical record is three years of silence claim 4unconfirmed in a classification created in March 2023 claim 1verified. Those two facts decide which capital number applies — low single-digit millions or mid-eight figures claim 15unconfirmed — the largest single swing in the file, and narrowable by reading the De Novo decision summary before anyone pays for a pre-submission.
What the week's evidence adds is a reason not to treat that silence as an opportunity. In the three years the classification sat unused, the incumbent published a 326-adult pivotal trial claim 31unconfirmed, accumulated a 220-patient real-world series claim 33unconfirmed, and took a federal supply contract covering five beneficiary populations claim 40unconfirmed. An empty classification with a first mover compounding advantages inside it is a different proposition from an empty classification nobody has entered, and the follower path being legally open would not by itself make it commercially open.
Naming it is not a recommendation, a gate, or a kill.
_shared/plain-language.md